Erasca, Inc. filed a current report on Form 8-K on August 24, 2026, disclosing that the U.S. Food and Drug Administration granted Fast Track Designation to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.

Key Highlights

  • Designation granted: The FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, according to the filing.
  • Purpose of Fast Track Designation: The company disclosed that FTD "is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs."
  • Potential benefits: Designated programs may be eligible for more frequent FDA interactions and, if relevant criteria are met, accelerated approval, priority review, and rolling review, the filing states.
  • No change to approval standards: The filing notes that "FTD does not change the standards for approval but may expedite the development or approval process."
  • FDA retains discretion: According to the filing, the FDA may later decide that ERAS-0015 no longer meets the conditions for FTD qualification or that the review period will not be shortened.
  • Planned trials referenced: The company's forward-looking statements reference a plan to initiate a phase 3 clinical trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer.

FDA Fast Track Designation for ERAS-0015 in Pancreatic Cancer

Erasca, Inc. (NASDAQ:ERAS) announced on August 24, 2026, that the FDA has granted Fast Track Designation to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. The disclosure was made under Item 8.01 (Other Events) of the Form 8-K filed the same day and signed by Chief Legal Officer Ebun Garner.

According to the filing, Fast Track Designation is designed to facilitate development and expedite the review of therapies addressing serious conditions with unmet medical needs. The filing notes that programs receiving this designation may benefit from more frequent FDA interactions and, if relevant criteria are met, could become eligible for accelerated approval, priority review, and rolling review. The company disclosed, however, that the designation does not alter the standards required for regulatory approval.

The filing includes cautionary language stating that the company's forward-looking statements, including those related to FTD potentially expediting development or regulatory review, are subject to risks and uncertainties. The company cautions that "FTD may not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that ERAS-0015 will receive marketing approval in the United States." Additional risk factors are described in the company's annual report on Form 10-K for the year ended December 31, 2025, and subsequent regulatory filings, according to the filing.

What Was Disclosed

Erasca disclosed in an August 24, 2026 Form 8-K that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. The filing details the potential benefits of the designation while noting that approval standards remain unchanged and the FDA retains broad discretion.